Key Developments: Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

98.81USD
3:13pm EDT
Price Change (% chg)

$0.11 (+0.11%)
Prev Close
$98.70
Open
$98.83
Day's High
$98.99
Day's Low
$98.33
Volume
1,126,773
Avg. Vol
2,065,185
52-wk High
$108.77
52-wk Low
$86.09

Search Stocks

Latest Key Developments (Source: Significant Developments)

Johnson & Johnson announces quarterly dividend for Q4 2014
Thursday, 16 Oct 2014 07:44am EDT 

Johnson & Johnson:Says Board has declared a cash dividend for the Q4 2014 of $0.70 per share on its common stock.Says dividend is payable on Dec. 9, to shareholders of record at the close of business on Nov. 25.  Full Article

Johnson & Johnson raises FY 2014 earnings guidance
Tuesday, 14 Oct 2014 07:45am EDT 

Johnson & Johnson:Increased FY 2014 earnings guidance to $5.92 - $5.97 per share.Says guidance excludes the impact of special items.FY 2014 EPS of $5.93 - Thomson Reuters I/B/E/S.  Full Article

Johnson & Johnson announces agreement to acquire Alios BioPharma
Tuesday, 30 Sep 2014 08:30am EDT 

Johnson & Johnson:Announces definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for about $1.75 billion in cash.The acquisition will include Alios BioPharma's portfolio of potential therapeutics for viral infections including compound AL-8176, an orally administered antiviral therapy currently in Phase 2 studies for the treatment of infants with respiratory syncytial virus.The transaction is expected to close during the fourth quarter of 2014.  Full Article

Johnson & Johnson announces $5 bln share repurchase program
Monday, 21 Jul 2014 05:00pm EDT 

Johnson & Johnson:Approves the repurchase of up to $5 billion of the company's common stock.Repurchases may be made at management's discretion from time to time on the open market or through privately negotiated transactions.  Full Article

Johnson & Johnson announces quarterly dividend for third quarter 2014
Monday, 21 Jul 2014 11:10am EDT 

Johnson & Johnson:Declares cash dividend for third quarter of 2014 of $0.70 per share on the company's common stock.Dividend is payable on Sept. 09, 2014 to shareholders of record at the close of business on Aug. 26, 2014.Ex-dividend date is Aug. 22, 2014.  Full Article

Johnson & Johnson raises FY 2014 earnings guidance
Tuesday, 15 Jul 2014 07:45am EDT 

Johnson & Johnson:Increased FY 2014 earnings guidance to $5.85 - $5.92 per share.Says guidance excludes the impact of special items.FY 2014 EPS of $5.90 - Thomson Reuters I/B/E/S.  Full Article

Johnson & Johnson completes divestiture of Ortho-Clinical Diagnostics To The Carlyle Group
Monday, 30 Jun 2014 04:30pm EDT 

Johnson & Johnson:Completes divestiture of Ortho-Clinical Diagnostics business to Carlyle Group for about $4 bln, subject to customary adjustments.Under terms of the transaction, The Carlyle Group has acquired the Ortho-Clinical Diagnostics business, global provider of solutions for screening, diagnosing, monitoring and confirming diseases.  Full Article

Johnson & Johnson announces dividend increase of 6.1 pct
Thursday, 24 Apr 2014 10:22am EDT 

Johnson & Johnson:Declared a 6.1 pct increase in the quarterly dividend rate, from $0.66 per share to $0.70 per share.Payable on June 10 to shareholders of record at the close of business on May 27.Ex-dividend date is May 22.  Full Article

Johnson & Johnson raises FY 2014 guidance - conference Call
Tuesday, 15 Apr 2014 08:30am EDT 

Johnson & Johnson:Expects FY 2014 sales growth to range between 4.5 pct and 5.5 pct for a total expected level of reported sales between $74.5 billion to $75.3 billion, which is higher than previous guidance.Expects FY 2014 EPS, excluding special items, in the range between $5.80 and $5.90 per share or a growth rate of between 5 pct and 7 pct.This is higher than previous guidance.FY 2014 revenue of $74.3 million and EPS of $5.83 - Thomson Reuters I/B/E/S.  Full Article

Johnson & Johnson announces acceptance of binding offer from The Carlyle Group to acquire ortho-clinical diagnostics
Monday, 31 Mar 2014 07:45am EDT 

Johnson & Johnson:Accepts the binding offer from The Carlyle Group, which was received and announced on Jan. 16 to acquire its Ortho-Clinical Diagnostics business for about $4 bln.The transaction is expected to close toward the middle of the year, upon satisfaction of customary closing conditions.  Full Article

Photo

J&J beats forecasts, helped by hepatitis drug

- Johnson & Johnson reported strong quarterly earnings on surging sales of a new treatment for hepatitis C, but the company said it had sharply reduced prices for its artificial hips and warned that profits could be hurt next year by the stronger dollar.

Search Stocks